AzTrials
AzTrials

Coronary Artery DiseaseNCT03146208

Role of Endothelial Biomarkers in Patients With Coronary Artery Disease

An observational study of Coronary Artery Disease and Diabetes Mellitus, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Coronary artery disease is a contraction of the coronary arteries that prevent adequate blood supply to the heart muscle is called CAD. Usually caused by atherosclerosis, it may be advanced to the point where the heart muscle is injured due to lack of blood supply. Read more about this study

Who is it for?
Ages 25 to 55 years
How many people
54 participants
Where
No sites listed yet
Study dates
1 Jul 2017to 20 Jan 2019
How long will I take part?
11 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 55 years
  • All sexes
  • Adult

Study population: The patients will be selected from Cardiology Department in Assiut University Hospital, according to American Heart Association, patients with manifestation of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing) with or without T2DM. All patients with risk factors such as hypertension, hyperlipidemia and smokers. The sample size was calculated using EPi Info 2000, version 1.1.2 (Center for disease control and prevention, Atlanta, Georgia, USA) based on proportion of telomere shortening in normal subjects range from 0-1% and it is expected to be 14 % in patients with coronary artery disease (Daily News, American Heart Association, 2016) using 90% confidence interval and 80% power, the sample size is 54 cases of coronary artery disease and 54 control subjects (total 108).

Who may be able to join

  • According to American Heart Association, patients with a manifestation of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing) with or without T2DM.
  • All patients with risk factors such as hypertension, hyperlipidemia and smokers.

Who cannot join

  • Psycological disorders
  • Cancers.
  • Strock.
  • Acute and chronic inflammation and Autoimmune diseases were excluded from the study.

Trial locations and contacts

No sites are listed yet.

About this study

Official title: Biomarkers of Coronary Artery Diseases

Coronary artery disease is a contraction of the coronary arteries that prevent adequate blood supply to the heart muscle is called CAD. Usually caused by atherosclerosis, it may be advanced to the point where the heart muscle is injured due to lack of blood supply. Such damage may result in infarction, arrhythmias, and heart failure(1,2).

Telomeres are short in circulating leucocytes in patients with coronary artery disease but the precise mechanism is not well-known (3).

Read more

Telomere and telomerase are affected by cytomegalovirus (CMV) infection due to its effect on increasing the number of highly differentiated T cells that are characterized by shorter telomere length (TL) and lowered telomerase activity (TA). Both genetic and environmental factors have been connected with individual distinction in TL.Cardiovascular risk factors such as smoking, diabetes mellitus, hypertension, obesity, and stress have been considered to upsurge inflammation, oxidative stress, therefore accelerating TL shortening (1,2)

It has also been observed that telomere loss in type 2 diabetic patients contributes to oxidative stress and endoplasmic reticulum stress while telomere shortening has also been proposed that it can serve as an independent risk factor of T2DM and it can measure disease progression(4).

Moreover, telomeric length in peripheral blood mononuclear cells (PBMCs) is associated with the duration of disease and good glycemic control seems to be protective for telomeric loss (5).

Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor (TGF)-β superfamily. GDF-15, recently identified as one of the new cardioprotective cytokines. It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk(6).

Dipeptidyl peptidase inhibitors (DPP4 -I) are called gliptins which increase the incretin levels and therefore prolong the post-prandial insulin action(7).

Diana et al reported that In type 2 diabetic patients, leukocyte telomere was significantly shorter than control groups and was significantly elongated after intervention by sitagliptin(8).

The common feature of all risk factors of CAD and T2DM imbalance between pro- and anti-oxidative factors in the organism with an increased production of reactive oxygen species (ROS).Nuclear factor erythroid-derived factor 2-related factor 2(Nrf2) is a family of transcription factors which plays an important role in protection against CVD and DM by regulating antioxidant enzymes in cells after ROS exposure (9).

In our study, we will propose a model, which would provide the basis to establish a marker for chronic reactivation of CMV and shed more light into the pathophysiology of CMV infection in patients with CAD in relation to GDF-15 and NrF2 and their implications on disease progression. Ultimately, this would then enable us to identify patients at risk and develop novel strategies for future treatment and prevention of heart diseases in our country. In light of our project research, the question arises whether telomere length could represent a marker of chronic CMV reactivation and uncertainty their length will be modified by the effect of DPP-4 or not?

Read the detailed description
  1. We are aiming to establish a marker for chronic reactivation and pathophysiology of CMV infection in patients with coronary artery disease.
  2. We will be able to answer whether there is a link between the seropositive CMV, telomere length, and CAD.
  3. We will correlate the seropositive CMV with telomere length, GDF-15 \& NRF2.
  4. We will detect the origin of our biomarkers by human umbilical vein endothelial cells(HUVECS).
  5. We will measure the effect of DPP4-I (on TL \& GDF-15 on cardiac cell line).
  6. We are looking to establish a new potential risk marker from our study, (GDF-15 \& NRF2) which could be tested in a larger cohort of patients. This would then enable us to identify CMV-seropositive patients at risk and develop novel strategies for future treatment and prevention.
Keywords
Growth differentiation factor-15, Dipeptidyl-peptidase inhibitors (DPP4 -I), Coronroy artery diseases
Medical subject headings
Coronary Artery Disease, Diabetes Mellitus, Cytomegalovirus Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03146208
Study groupRoleWhat they receive
Coronary artery disease patients with type 2 DMCoronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
Coronary artery disease patients without type 2 DMThe present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
Healthy control groupwe will include 54 age-matched patients with normal angiogram

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Role of endothelial bio markers in patients with coronary artery disease

    genetic expression of new bio markers in coronary artery diseases

    Measured: two years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 May 2017
  2. Study start1 Jul 2017 (estimated)
  3. Primary completion15 Oct 2018 (estimated)
  4. Study completion20 Jan 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
54 participants (estimated)
Target duration
11 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT03146208
Sponsor's protocol ID
17200057
Status last verified
May 2017
First submitted
6 May 2017
Last updated
9 May 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Qi Nan W, Ling Z, Bing C. The influence of the telomere-telomerase system on diabetes mellitus and its vascular complications. Expert Opin Ther Targets. 2015 Jun;19(6):849-64. doi: 10.1517/14728222.2015.1016500. Epub 2015 Feb 13.

    PubMed 25677239

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease and Diabetes Mellitus, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 May 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Abdelrehim Mekii, PROF (0201008423366 ext. 2411988, meki202000@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Role of endothelial bio markers in patients with coronary artery disease (time frame: two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03146208, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in